What is the recommended treatment for tetanus?

Treatment for Tetanus

For active tetanus infection, immediate treatment requires comprehensive wound debridement, tetanus immune globulin (TIG) 500 IU intramuscularly, metronidazole 500 mg IV every 6-8 hours (or penicillin G 2-4 million units IV every 4-6 hours), benzodiazepines for muscle spasm control, and intensive care support with mechanical ventilation for severe cases. 1, 2

Immediate Management of Active Tetanus

Source Control and Antitoxin

• Wound debridement is critical - surgically remove all devitalized tissue and foreign material to eliminate the anaerobic environment where C. tetani spores germinate 3
• Administer TIG 500 IU intramuscularly as soon as possible to neutralize circulating toxin (note: this does NOT affect toxin already bound to neurons) 4, 1
• Human TIG is equivalent to equine antitoxin in efficacy, with no clinically significant difference in outcomes 4
• Intrathecal antitoxin does NOT provide additional benefit beyond intramuscular administration and should not be routinely used 4

Antibiotic Therapy

• Metronidazole 500 mg IV every 6-8 hours for 7-10 days is the preferred antibiotic 2
• Alternative: Penicillin G 2-4 million units IV every 4-6 hours, though metronidazole is preferred as penicillin may theoretically worsen spasms due to GABA antagonism 2

Spasm Control and Supportive Care

• Benzodiazepines are first-line for controlling muscle spasms - use high-dose diazepam or midazolam titrated to effect 2
• Magnesium sulfate can be added for refractory spasms and autonomic instability 1, 2
• Mechanical ventilation is required in 40-50% of severe cases due to laryngospasm, respiratory muscle rigidity, or medication-induced respiratory depression 4, 1
• Expect prolonged ICU stays of several weeks with high risk of nosocomial infections 1

Active Immunization

• Administer tetanus toxoid vaccine during acute illness, as natural infection does NOT confer immunity 2, 5
• Complete the full 3-dose primary series after recovery if vaccination history is incomplete 6, 3

Tetanus Prophylaxis for Wound Management

The decision to give tetanus vaccine and/or TIG depends on vaccination history and wound characteristics 7:

For Clean, Minor Wounds

• Give tetanus vaccine if ≥10 years since last dose 7
• No TIG needed regardless of vaccination history 7
• Use Tdap for persons ≥11 years who haven't received Tdap previously; otherwise use Td 7

For All Other Wounds (Contaminated, Puncture, Crush, Burns)

• Give tetanus vaccine if ≥5 years since last dose 7
• Give TIG 250 IU IM if vaccination history unknown or <3 doses received 7
• When both vaccine and TIG are indicated, administer at separate anatomic sites using different syringes 7

Special Populations

• HIV/severely immunocompromised patients with contaminated wounds: Give TIG regardless of vaccination history 7
• Pregnant women: Use Tdap if tetanus vaccine is indicated 7
• Persons ≥60 years and immigrants from non-North American/European regions: Prioritize for TIG if supplies are limited, as they are least likely to have protective antibody levels 3

Primary Vaccination for Unvaccinated or Incompletely Vaccinated Adults

Adults with unknown or incomplete vaccination history should receive a 3-dose primary series 7, 6:

• Preferred schedule: Single dose of Tdap, followed by Td at least 4 weeks later, then another Td dose 6-12 months after the second dose 7, 6
• Tdap can substitute for any of the three Td doses in the series 7, 6
• Alternative approach: If vaccination history is uncertain but likely received, consider serologic testing - if tetanus and diphtheria antitoxin levels are each >0.01 IU/mL (some sources use >0.1 IU/mL), give single Tdap dose only 7, 6

Critical Pitfalls to Avoid

• Do not delay TIG or vaccine while awaiting vaccination records - treat based on patient's stated history; unnecessary vaccination is safer than missing needed prophylaxis 3
• Do not give tetanus vaccine within 10 years of an Arthus reaction to a previous tetanus-containing vaccine, even for contaminated wounds - the decision for TIG is based solely on primary vaccination history 7
• Do not assume natural tetanus infection provides immunity - always vaccinate during or after recovery 2, 5
• Do not use intrathecal antitoxin routinely - a high-quality 2022 RCT showed no benefit over intramuscular administration 4

Prognosis

Mortality remains 10-20% even with modern intensive care 3, 1. Without access to mechanical ventilation, mortality is substantially higher 1. The case-fatality ratio in the U.S. during 1998-2000 was 18% 3. Survivors typically have good functional outcomes but require weeks of hospitalization 1, 5.

Human versus equine antitoxin showed equivalent efficacy in the most recent high-quality trial, so either can be used based on availability 4.